SecBot SecBot
SECBOTREPLAY Home › Report › SNY

SNY · Sanofi reported H1 2026 net sales of €22,106M (+11.1% reported, +15.7%…

Sanofi · 6-K filed Jul 30, 2026 at 07:34 ET

At the news

MIXEDIMPACT 6/10

6-K filed Jul 30, 2026 at 07:34 ET

Sanofi reported H1 2026 net sales of €22,106M (+11.1% reported, +15.7% CER), driven by Dupixent (+34.4% CER) and new launches. Business EPS rose 17.1% to €3.97, and guidance was raised to ~10% CER sales growth for FY2026, with Business EPS growing slightly faster. However, IFRS net income fell 66.3% to €1,957M, largely due to a €1,031M impairment (€952M for discontinued amlitelimab) and the prior-year Opella divestiture gain. The underlying business performance is strong, but the pipeline setback and elevated restructuring costs temper the outlook.

  • H1 2026 net sales: €22,106M, +11.1% reported, +15.7% CER vs H1 2025
  • Business EPS: €3.97, +17.1% vs €3.39 in H1 2025
  • IFRS net income attributable to equity holders: €1,957M, down from €5,812M (H1 2025 included €2,693M Opella gain)
  • Dupixent sales: €9,324M, +27.5% reported, +34.4% CER

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access